Dyslipidemie

Unstoppable commitment to ASCVD care for over 10 years

PCSK9 inhibitor treatment and outcomes

Why choose PRALUENT®?

Understanding Cardiovascular Risk and Prevention: Insights from Professor Pasquale Perrone-Filardi

Preventive Cardiology: Key Insights from Professor Michal Vrablik

A phase III randomized trial evaluating alirocumab 300 mg every 4 weeks as monotherapy or add-on to statin: ODYSSEY CHOICE I

Roth Eli M et al. Atherosclerosis vol. 254 (2016): 254-262